Search

Your search keyword '"Tuleta, Izabela"' showing total 242 results
Start Over Author "Tuleta, Izabela"
242 results on '"Tuleta, Izabela"'

1. HERV-W upregulation expression in bipolar disorder and schizophrenia: unraveling potential links to systemic immune/inflammation status

Author

Rangel, Sara Coelho, da Silva, Michelly Damasceno, Natrielli Filho, Décio Gilberto, Santos, Samuel Nascimento, do Amaral, Jonatas Bussador, Victor, Jefferson Russo, Silva, Kevin Cezar Nascimento, Tuleta, Izabela Dorota, França, Carolina Nunes, Shio, Marina Tiemi, Neves, Lucas Melo, Bachi, André Luis Lacerda, and da Silva Nali, Luiz Henrique

Published
2024
Full Text
View/download PDF

6. An International Multicenter Evaluation of Type 5 Long QT Syndrome

Author

Roberts, Jason D, Asaki, S Yukiko, Mazzanti, Andrea, Bos, J Martijn, Tuleta, Izabela, Muir, Alison R, Crotti, Lia, Krahn, Andrew D, Kutyifa, Valentina, Shoemaker, M Benjamin, Johnsrude, Christopher L, Aiba, Takeshi, Marcondes, Luciana, Baban, Anwar, Udupa, Sharmila, Dechert, Brynn, Fischbach, Peter, Knight, Linda M, Vittinghoff, Eric, Kukavica, Deni, Stallmeyer, Birgit, Giudicessi, John R, Spazzolini, Carla, Shimamoto, Keiko, Tadros, Rafik, Cadrin-Tourigny, Julia, Duff, Henry J, Simpson, Christopher S, Roston, Thomas M, Wijeyeratne, Yanushi D, El Hajjaji, Imane, Yousif, Maisoon D, Gula, Lorne J, Leong-Sit, Peter, Chavali, Nikhil, Landstrom, Andrew P, Marcus, Gregory M, Dittmann, Sven, Wilde, Arthur AM, Behr, Elijah R, Tfelt-Hansen, Jacob, Scheinman, Melvin M, Perez, Marco V, Kaski, Juan Pablo, Gow, Robert M, Drago, Fabrizio, Aziz, Peter F, Abrams, Dominic J, Gollob, Michael H, Skinner, Jonathan R, Shimizu, Wataru, Kaufman, Elizabeth S, Roden, Dan M, Zareba, Wojciech, Schwartz, Peter J, Schulze-Bahr, Eric, Etheridge, Susan P, Priori, Silvia G, and Ackerman, Michael J

Subjects
Genetics, Cardiovascular, Clinical Trials and Supportive Activities, Heart Disease, Clinical Research, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Adolescent, Adult, Death, Sudden, Cardiac, Electric Countershock, Electrocardiography, Female, Heart Arrest, Humans, Long QT Syndrome, Male, Middle Aged, Penetrance, Potassium Channels, Voltage-Gated, Registries, arrhythmia, genetics, long QT syndrome, penetrance, sudden cardiac death, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Public Health and Health Services, Cardiovascular System & Hematology
Abstract

BackgroundInsight into type 5 long QT syndrome (LQT5) has been limited to case reports and small family series. Improved understanding of the clinical phenotype and genetic features associated with rare KCNE1 variants implicated in LQT5 was sought through an international multicenter collaboration.MethodsPatients with either presumed autosomal dominant LQT5 (N = 229) or the recessive Type 2 Jervell and Lange-Nielsen syndrome (N = 19) were enrolled from 22 genetic arrhythmia clinics and 4 registries from 9 countries. KCNE1 variants were evaluated for ECG penetrance (defined as QTc >460 ms on presenting ECG) and genotype-phenotype segregation. Multivariable Cox regression was used to compare the associations between clinical and genetic variables with a composite primary outcome of definite arrhythmic events, including appropriate implantable cardioverter-defibrillator shocks, aborted cardiac arrest, and sudden cardiac death.ResultsA total of 32 distinct KCNE1 rare variants were identified in 89 probands and 140 genotype positive family members with presumed LQT5 and an additional 19 Type 2 Jervell and Lange-Nielsen syndrome patients. Among presumed LQT5 patients, the mean QTc on presenting ECG was significantly longer in probands (476.9±38.6 ms) compared with genotype positive family members (441.8±30.9 ms, P

Published
2020

9. Role of circulating microparticles and cytokines in periodontitis associated with diabetes.

Author

Adelungue Cassiano, Bárbara, Pereira Assunção Silveira, Ana Luíza, Yeon Jung Kim, Bussador do Amaral, Jônatas, da Silva Nali, Luiz Henrique, Lacerda Bachi, André Luis, Diniz Resende, Leonardo, Helfenstein Fonseca, Francisco Antonio, de Oliveira Izar, Maria Cristina, Dorota Tuleta, Izabela, Victor, Jefferson Russo, Pallos, Débora, and Nunes França, Carolina

Published
2024
Full Text
View/download PDF

19. Persistence of a proinflammatory status after treatment of the acute myocardial infarction

Author

da Silva, Leandro Santos, primary, Germano, Danielle Borges, additional, Fonseca, Francisco Antonio Helfenstein, additional, Shio, Marina Tiemi, additional, da Silva Nali, Luiz Henrique, additional, Tuleta, Izabela Dorota, additional, Juliano, Yára, additional, de Oliveira Izar, Maria Cristina, additional, Ribeiro, Ana Paula, additional, Kato, Juliana Tieko, additional, do Amaral, Jônatas Bussador, additional, and França, Carolina Nunes, additional

Published
2023
Full Text
View/download PDF

22. Monocytes presenting a pro-inflammatory profile persist in patients submitted to a long-term pharmacological treatment after acute myocardial infarction

Author

de Carvalho, Daniel Carneiro, primary, Fonseca, Francisco Antonio Helfenstein, additional, Izar, Maria Cristina de Oliveira, additional, Silveira, Ana Luíza Pereira Assunção, additional, Tuleta, Izabela Dorota, additional, do Amaral, Jônatas Bussador, additional, Neves, Lucas Melo, additional, Bachi, André Luis Lacerda, additional, and França, Carolina Nunes, additional

Published
2023
Full Text
View/download PDF

24. Cardiac allograft vasculopathy in a long-term follow-up after heart transplantation: Role of remnant cholesterol in residual inflammation

Author

Alyaydin, Emyal, Pogoda, Christian, Dell'Aquila, Angelo Maria, Martens, Sven, Tuleta, Izabela, Reinecke, Holger, Sindermann, Jürgen, and Universitäts- und Landesbibliothek Münster

Subjects
610 Medicine and health, Medicine and health, cardiac allograft vasculopathy, remnant cholesterol, statin treatment, heart transplantation, ddc:610
Abstract

Background: Cardiac allograft vasculopathy (CAV) is a major prognosis limiting factor in heart transplantation (HTx). Disease development and progression are influenced by multiple determinants, but the role of remnant cholesterol (RC) in CAV has not yet been investigated. Therefore, the present study aimed to assess the prevalence of CAV in a very long-term follow-up after orthotopic HTx and to examine the role of RC in residual inflammation despite secondary prevention. Methods: Herein, is a retrospective analysis of patient data collected at the last follow-up visit in an outpatient setting. Additionally, RC levels were calculated based upon cholesterol profile. Results: The study population consisted of 184 patients with a mean follow-up of 15.0 ± 6.8 years. More than 40% of the overall cohort had CAV at last follow-up. The mean RC was 27.1 ± 14.7 mg/dL. Patients with CAV had significantly elevated RC despite intensified statin treatment (p = 0.018). A positive correlation was observed between RC and interleukin-6 as a marker of residual inflammation. Elevated RC and prolonged follow-up emerged as significant factors related to CAV in a multivariate analysis (odds ratio [OR] 2.9, 95% confidence interval [CI] 1.5–5.5, p = 0.001 and OR 3.3, 95% CI 1.4–7.7, p = 0.006, respectively), whereas mycophenolate mofetil was inversely associated with CAV (OR 0.4, 95% CI 0.2–0.9, p = 0.034). Conclusions: Remnant cholesterol has proinflammatory properties and is associated with CAV development in HTx. Thus, RC should be concerned as an additional tool for risk assessment., Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster).

Published
2022

25. Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome

Author

Fröb, Elisabeth, Sindermann, Jürgen, Reinecke, Holger, Tuleta, Izabela, and Universitäts- und Landesbibliothek Münster

Subjects
610 Medicine and health, Medicine and health, CRP, Sacubitril/valsartan, NYHA class, Chronic heart failure with reduced left ventricular ejection fraction, Hospitalization rates, ddc:610
Abstract

Background: Currently, data on sacubitril/valsartan therapy from the real-world settings are scarce and the predictors of a good clinical responsiveness to this drug are unknown. Objectives: To assess efficacy and safety profile of sacubitril/valsartan and to identify predictors for a better clinical outcome. Materials and methods: Clinical, laboratory and echocardiographic data of 95 chronic heart failure (CHF) patients with reduced ejection fraction (HFrEF) were retrospectively analyzed. A good efficacy of sacubitril/valsartan was defined as the fulfilment of at least 2 of the following criteria: improvement of left ventricular ejection fraction (LVEF) or functional status, and reduction of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels or hospitalization rates. Results: Under sacubitril/valsartan, major improvements were observed in LVEF, the New York Heart Association (NYHA) class, NT-proBNP levels, and hospitalization rates. Patients with a good efficacy of sacubitril/valsartan were characterized by initially worse LVEF (median (interquartile range (IQR)): 29.0% (23.0–33.0%) compared to 32.0% (28.5–38.0%) with more frequent nonischemic etiology (65.4% compared to 41.9%) and hospitalizations for CHF/month (0.016 (0.004–0.057) compared to 0.000 (0.000–0.012)), lower cholesterol (42.3% compared to 65.1%), higher C-reactive protein (CRP) levels at baseline (0.5 mg/L (0.5–1.0 mg/L) compared to 0.5 mg/L (0.5–0.5 mg/L)), and a shorter timespan between CHF diagnosis and the start of sacubitril/valsartan treatment (66.0 (11.0–127.0) compared to 111 (73.0–211.0) months) (p < 0.05 each). In a multivariate Cox analysis, only the last 2 parameters were shown to be independent predictors of good clinical responsiveness to sacubitril/valsartan (hazard ratio (HR) = 1.263, 95% confidence interval (95% CI) = [1.048; 1.521]; HR = 0.992, 95% CI = [0.987; 0.997], p < 0.05, respectively). Conclusions: Sacubitril/valsartan improved LVEF, NYHA class, NT-proBNP levels, and hospitalization rates, mostly without relevant side effects. The independent predictors of a good clinical efficacy were higher CRP levels at baseline and a shorter delay between CHF diagnosis and the initialization of sacubitril/valsartan therapy., Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster).

Published
2022

33. ATIVIDADE FÍSICA E SINTOMAS DE ANSIEDADE E DEPRESSÃO ENTRE ESTUDANTES DE MEDICINA DURANTE A PANDEMIA

Author

Mendes, Tassia Barcelos, Souza, Karla Cardoso de, França, Carolina Nunes, Rossi, Fabrício Eduardo, Santos, Rafael Pereira Guimarães, Duailibi, Kalil, Tuleta, Izabela, Armond, Jane de Eston, Stubbs, Brendon, and Neves, Lucas Melo

Subjects
Coronavirus, Coronavírus, Sedentary behavior, University, COVID-19, Universidades, Exercício físico, Conducta sedentaria, Exercise, Ejercicio físico, Comportamento sedentário
Abstract

Introduction: Decreased physical activity has been associated with poorer mental health and is a cause for concern during the COVID-19 pandemic. Objective: To compare groups of medical students (MS) who practiced different levels of moderate and vigorous physical activity (MVPA) during the COVID-19 pandemic, in relation to symptoms of anxiety and depression (BAI-BDI), sleep quality (PSQI), and physical activity (PA) - light, moderate, vigorous (LPA-MPA and VPA), and sedentary behavior (SB). Methods: This research is a cross-sectional study involving 218 MS. Data on the characteristics of the MS were collected through online forms: PA, SB, BAI, BDI, and PSQI. The Cohen's D (Effect Size - ES) and confidence interval (95% CI), Mann-Whitney test: Lower MVPA (Median=0 minute) and Higher MVPA (Median=390 minutes) were recorded. For the statistical analyses, we used: the Odds ratio (OR) for the presence of symptoms of high levels of anxiety and depression and poor sleep quality in the MS and MVPA. Results: We found a small ES for symptoms of depression (ES 0.26 95% CI 0.00 0.53 p=0.029), and significant differences (p

Published
2021

34. PHYSICAL ACTIVITY AND SYMPTOMS OF ANXIETY AND DEPRESSION AMONG MEDICAL STUDENTS DURING A PANDEMIC

Author

Mendes, Tassia Barcelos, primary, Souza, Karla Cardoso de, additional, França, Carolina Nunes, additional, Rossi, Fabrício Eduardo, additional, Santos, Rafael Pereira Guimarães, additional, Duailibi, Kalil, additional, Tuleta, Izabela, additional, Armond, Jane de Eston, additional, Stubbs, Brendon, additional, and Neves, Lucas Melo, additional

Published
2021
Full Text
View/download PDF

45. Heart Failure Results in Inspiratory Muscle Dysfunction Irrespective of Left Ventricular Ejection Fraction

Author

Spiesshoefer, Jens, primary, Henke, Carolin, additional, Kabitz, Hans Joachim, additional, Bengel, Philipp, additional, Schütt, Katharina, additional, Nofer, Jerzy-Roch, additional, Spieker, Maximilian, additional, Orwat, Stefan, additional, Diller, Gerhard Paul, additional, Strecker, Jan Kolia, additional, Giannoni, Alberto, additional, Dreher, Michael, additional, Randerath, Winfried Johannes, additional, Boentert, Matthias, additional, and Tuleta, Izabela, additional

Published
2020
Full Text
View/download PDF

46. Adaptive servo-ventilation therapy does not favourably alter sympatho-vagal balance in sleeping patients with systolic heart failure and central apnoeas: Preliminary data

Author

Gorbachevski, Martha, primary, Spiesshoefer, Jens, additional, Arzt, Michael, additional, Oldenburg, Olaf, additional, Becker, Sara, additional, Tuleta, Izabela, additional, Emdin, Michele, additional, Passino, Claudio, additional, Sciarrone, Paolo, additional, Boentert, Matthias, additional, and Giannoni, Alberto, additional

Published
2020
Full Text
View/download PDF

47. Effects of central apneas on sympathovagal balance and hemodynamics at night: impact of underlying systolic heart failure

Author

Spiesshoefer, Jens, primary, Hegerfeld, Nora, additional, Gerdes, Malte Frank, additional, Klemm, Sören, additional, Gorbachevski, Martha, additional, Radke, Robert, additional, Tuleta, Izabela, additional, Passino, Claudio, additional, Jiang, Xiaoyi, additional, Sciarrone, Paolo, additional, Randerath, Winfried, additional, Dreher, Michael, additional, Boentert, Matthias, additional, and Giannoni, Alberto, additional

Published
2020
Full Text
View/download PDF

49. Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations.

Author

Fomin, Andrey, Gärtner, Anna, Cyganek, Lukas, Tiburcy, Malte, Tuleta, Izabela, Wellers, Luisa, Folsche, Lina, Hobbach, Anastasia J., von Frieling-Salewsky, Marion, Unger, Andreas, Hucke, Anna, Koser, Franziska, Kassner, Astrid, Sielemann, Katharina, Streckfuß-Bömeke, Katrin, Hasenfuss, Gerd, Goedel, Alexander, Laugwitz, Karl-Ludwig, Moretti, Alessandra, and Gummert, Jan F.

Subjects
CONNECTIN, INDUCED pluripotent stem cells, MYOCARDIUM, GENETIC variation, PROTEINS, DILATED cardiomyopathy
Abstract

Tracking titin in dilated cardiomyopathy: Truncating variants in TTN, the gene encoding the titin protein, underlie 15 to 25% of cases of nonischemic dilated cardiomyopathy (DCM), but whether the disease is caused by haploinsufficiency or the presence of truncated titin proteins is not yet clear. Here, using tissues from the hearts of patients with DCM and TTN truncating variants as well as human induced pluripotent stem cells differentiated into cardiomyocytes, Fomin et al. and McAfee et al. identified both the presence of truncated titin proteins and less-abundant full-length titin proteins. These findings suggest that the presence of truncated titin proteins as "poison peptides" and titin haploinsufficiency both contribute to the pathogenesis of disease and should support the investigation of targeted therapies to treat DCM caused by TTN truncating variants. Heterozygous truncating variants in TTN (TTNtv), the gene coding for titin, cause dilated cardiomyopathy (DCM), but the underlying pathomechanisms are unclear and disease management remains uncertain. Truncated titin proteins have not yet been considered as a contributor to disease development. Here, we studied myocardial tissues from nonfailing donor hearts and 113 patients with end-stage DCM for titin expression and identified a TTNtv in 22 patients with DCM (19.5%). We directly demonstrate titin haploinsufficiency in TTNtv-DCM hearts and the absence of compensatory changes in the alternative titin isoform Cronos. Twenty-one TTNtv-DCM hearts in our cohort showed stable expression of truncated titin proteins. Expression was variable, up to half of the total titin protein pool, and negatively correlated with patient age at heart transplantation. Truncated titin proteins were not detected in sarcomeres but were present in intracellular aggregates, with deregulated ubiquitin-dependent protein quality control. We produced human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs), comparing wild-type controls to cells with a patient-derived, prototypical A-band-TTNtv or a CRISPR-Cas9–generated M-band-TTNtv. TTNtv-hiPSC-CMs showed reduced wild-type titin expression and contained truncated titin proteins whose proportion increased upon inhibition of proteasomal activity. In engineered heart muscle generated from hiPSC-CMs, depressed contractility caused by TTNtv could be reversed by correction of the mutation using CRISPR-Cas9, eliminating truncated titin proteins and raising wild-type titin content. Functional improvement also occurred when wild-type titin protein content was increased by proteasome inhibition. Our findings reveal the major pathomechanisms of TTNtv-DCM and can be exploited for new therapies to treat TTNtv-related cardiomyopathies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results